RBC haemoglobinopathies
Content Summary
Red Blood Cell Haemoglobinopathies: Focus on Thalassaemia and Sickle Cell Anaemia
A Comprehensive Review of Pathophysiology, Epidemiology, and Management
Introduction
Haemoglobinopathies are inherited disorders affecting haemoglobin’s structure or production.
Thalassaemia and Sickle Cell Anaemia are globally significant diseases, with particular prevalence in specific populations in the UK and Greater London.
Inheritance of Haemoglobinopathies
Both thalassaemia and sickle cell disease follow an autosomal recessive inheritance pattern.
Individuals must inherit two mutated alleles (one from each parent) to manifest the disease.
Carriers (heterozygotes) inherit only one mutated allele and are usually asymptomatic but can pass the mutation to their offspring.
Prevalence of Haemoglobinopathies
About 7% of the global population carries an abnormal haemoglobin gene, with >500,000 affected children born annually.
More than 70% have a sickle disorder; the rest have thalassaemia syndromes.
Many affected children in developing countries die undiagnosed, misdiagnosed, or untreated.
Epidemiology: UK Perspective and Greater London
Over 15,000 individuals with Sickle Cell Anaemia and ~1,000 with severe forms of Thalassaemia in the UK.
Most cases found in Black African, Caribbean, and South Asian communities.
Greater London has the highest prevalence due to its diverse population.
1 in 8 births in London are from at-risk ethnic groups.
Disparities in healthcare access and outcomes persist.
Haemoglobin Formation
Structure of Haemoglobin:
Tetrameric protein composed of two alpha (α) and two beta (β) globin chains.
Each globin chain binds a haem group containing iron, essential for oxygen transport.
Pathophysiology of Thalassaemia
Thalassaemia arises from mutations leading to reduced or absent production of alpha or beta globin chains.
Imbalance causes precipitation of unpaired chains, resulting in ineffective erythropoiesis, haemolysis, and anaemia.
Key types: Alpha-thalassaemia and Beta-thalassaemia, based on the affected globin chain.
Genetic Variations in Thalassaemia
Alpha-thalassaemia:
Caused by deletions or mutations in the HBA1 or HBA2 genes (on chromosome 16), reducing alpha chain production.
Four alpha genes total (two per chromosome). Severity depends on number of affected genes.
Subtypes:
Alpha plus (α⁺) thalassaemia carrier (silent carrier): One non-functional gene. Asymptomatic; diagnosed via DNA analysis.
Alpha zero (α⁰) thalassaemia carrier: Two non-functional genes (cis or trans position).
HbH disease: Three non-functional genes. Excess β-chains form HbH (β₄). Unstable → haemolysis → moderate-severe anaemia, bone deformation, gallstones, splenomegaly.
Haemoglobin Bart’s – Hydrops Fetalis: All four alpha genes non-functional. Free γ-chains form Hb Bart’s (γ₄), which cannot carry oxygen → fatal in utero or shortly after birth.
Beta-thalassaemia:
Results from mutations in the HBB gene (on chromosome 11).
~200 different point mutations affecting transcription, RNA processing, translation, or post-translational integrity.
Mutation Types:
Transcription mutations: Promoter region base substitutions.
RNA processing mutations: Splicing signal alterations.
Translation mutations: Nonsense or frameshift mutations.
Clinical Severity:
β-thalassaemia major (β⁰): Homozygous; no β-globin production. Severe transfusion-dependent anaemia, ineffective erythropoiesis, bone marrow expansion.
β-thalassaemia intermedia (β⁺): Reduced β-globin production. Moderate anaemia, occasional transfusions.
β-thalassaemia minor (β⁺⁺): Heterozygous; asymptomatic or mild anaemia.
Management of Thalassaemia
Blood transfusion therapy to maintain Hb >70 g/L.
Iron chelation therapy (deferoxamine, deferasirox, deferiprone) to prevent iron overload.
Supportive care: Folic acid, monitoring for complications (liver, heart, endocrine, bone, dental).
Curative treatments: Bone marrow transplantation (HSCT), gene therapy.
Emerging therapies: Ruxolitinib, sotatercept, luspatercept (not all approved in UK).
Pathophysiology of Sickle Cell Anaemia
Mutation in HBB gene → substitution of valine for glutamic acid at position 6 of β-globin chain → forms Haemoglobin S (HbS).
Under deoxygenated conditions, HbS polymerises → red cells sickle → vaso-occlusion, haemolysis, chronic inflammation.
Sickle Cell Disease (SCD) – Evolutionary Aspects
Sickle cell trait (HbAS) provides survival advantage against malaria (Plasmodium falciparum).
Infected RBCs sickle and are destroyed → prevents parasite proliferation.
High frequency of HbS in malaria-endemic regions.
SCD Prevalence
Originated in Africa and India.
Prevalent in Arab world, Mediterranean countries (Greece, Turkey, Southern Italy).
Migrations have spread the gene worldwide.
Haemoglobinopathies Causing Sickle Cell Disease
Sickle cell trait (HbAS): Usually asymptomatic; risk of splenic infarction only in severe hypoxia.
Sickle cell disease (HbSS): Homozygous; severity varies. Symptoms appear after neonatal period (once HbF declines).
Sickle-thalassaemia disease: Inherit one sickle gene + one beta-thalassaemia gene. Severity depends on β-globin production.
Sickle cell C disease (HbSC): Lysine substitution at β6. Milder systemic symptoms but severe ocular pathology.
HbSE: Heterozygous for sickle + E mutation → mild anaemia.
HbS with α-thalassaemia: Reduced α-globin → less HbS → milder symptoms.
Clinical Manifestations of Sickle Cell Disease
Painful crises (vaso-occlusive).
Infant/childhood complications: Dactylitis, infections, acute splenic sequestration.
Acute chest syndrome: Leading cause of early death.
Strokes (overt and silent).
Chronic anaemia.
Avascular necrosis (hips, shoulders).
Osteomyelitis, osteoporosis.
Leg ulcers.
Gallstones, liver disease.
Kidney problems.
Priapism.
Eye complications.
Iron overload (from transfusions).
Increased infection risk.
Psychosocial impact.
Sickle Cell Disease (SCD) Management
Screening and Assessment:
Transcranial Doppler (TCD) annually from age 2 for stroke risk.
Iron overload monitoring: Serum ferritin, liver iron concentration.
Organ function testing: Kidney, liver, lungs, eyes.
Acute crisis: Vital signs, pain assessment, CBC, blood cultures, imaging.
Acute Complications Management:
Vaso-occlusive crises: Hydration, analgesia (opioids, NSAIDs), non-pharmacological support.
Acute chest syndrome: Oxygen, antibiotics, exchange transfusion.
Severe anaemia: Blood transfusion/exchange.
Infections: Prompt antibiotics.
Disease-Modifying Therapies:
Hydroxycarbamide (Hydroxyurea): Increases HbF. Dose: 15–20 mg/kg/day. Monitor CBC, LFTs.
Blood transfusions: Acute/chronic regimens. Complications: iron overload, alloimmunization.
Bone marrow transplantation (HSCT): Curative for severe disease in young patients with donors.
Prevention Strategies:
Vaccinations: Pneumococcal, meningococcal, Hib, influenza, hepatitis B.
Prophylactic antibiotics: Penicillin V (or erythromycin).
Folic acid supplementation: 5 mg daily.
Patient education: Hydration, temperature avoidance, crisis recognition.
Chronic Complications Management:
Stroke prevention: Annual TCD, chronic transfusions.
Renal/pulmonary: BP control, ACE inhibitors, early intervention for pulmonary hypertension.
Eye/bone: Annual ophthalmology exams; bisphosphonates for osteoporosis.
Chronic pain/leg ulcers: Multidisciplinary care.
Other Considerations:
Growth monitoring.
Priapism management: Gentle exercise, warmth, hydration; hospital if >1 hour.
Sleep apnoea and nocturnal enuresis common.
Long-Term Monitoring and Community Care:
Regular specialist reviews.
Community-based support and home management.
New and Emerging Therapies for SCD
HbS Polymerization Blockers – Voxelotor (Oxbryta™): Increases O₂ affinity → reduces polymerisation. Withdrawn in UK/EU due to safety concerns.
Cell Adhesion Inhibitors – Crizanlizumab (Adakveo®): Monoclonal antibody blocks P-selectin → reduces VOCs. Withdrawn in EU/UK after trial inconsistencies.
Gene Therapy:
Exagamglogene Autotemcel (Casgevy): CRISPR-based → edits BCL11A to reactivate HbF. FDA and NHS approved.
Lovotibeglogene Autotemcel (Lyfgenia): Lentiviral vector delivers healthy β-globin gene. FDA approved; not yet in UK.
CRISPR Technology:
CRISPR-Cas9 allows precise DNA editing.
In SCD: disrupts BCL11A enhancer → re-expresses fetal haemoglobin (HbF).
Process: Collect patient’s stem cells → edit ex vivo → reinfuse after myeloablative conditioning (e.g., busulfan).
Benefits: Potential one-time cure.
Limitations: Requires chemotherapy/radiotherapy, high cost, limited access.
Screening
Methods: CBC, haemoglobin electrophoresis, DNA analysis.
Importance: Early carrier detection during pregnancy; genetic counselling.
NHS: Routine screening for all pregnant women in UK, focusing on high-risk groups.
Equality, Diversity, Inclusion (EDI) and Stigma Issues
Patients often face stigma and are misjudged as drug-seeking during pain crises → delays in treatment.
Need for education, awareness campaigns, culturally competent care.
Case example: Evan Smith (21-year-old died in 2019) – failures in recognition, pain management, communication, and racial disparities.
Key Pioneer: Elizabeth Anionwu – first sickle cell/thalassaemia nurse consultant in UK; advocate for equity.
Follow-Up Question
Which organ can be removed in these patients, what prophylactic treatment needs to be given?
(Implied: Splenectomy may be performed in some cases; requires prophylactic antibiotics and vaccinations post-removal.)
Revision Questions
Inheritance pattern of SCD and thalassaemia: Autosomal recessive.
Abnormal haemoglobin when three α-globin genes deleted: HbH (β₄).
Characteristic feature of β-thalassaemia major: Complete absence of β-globin synthesis.
Mutation in SCD: Glutamic acid → Valine on β-chain.
Evolutionary advantage of HbAS in malaria-endemic areas: Infected RBCs sickle and are destroyed by immune system.
Correct statement about Casgevy: Edits BCL11A gene to reactivate fetal haemoglobin (HbF).
Case Study: Amira (22-year-old with HbSS)
Presentation: Severe bone pain, recent respiratory infection, dehydration.
Vitals: Temp 37.8°C, HR 110, BP 108/65, O₂ sat 94%.
Labs: Hb 75 g/L, high reticulocytes, WBC 12×10⁹/L.
Questions:
Most likely cause: Vaso-occlusive (painful) crisis.
Most appropriate initial management: Administer high-flow oxygen and analgesia with IV fluids.
How hydroxyurea benefits SCD: Stimulates production of fetal haemoglobin (HbF).
QUESTIONS:
Section 1: Single Best Answer (SBA) Questions
Q1:
A 4-year-old child with beta-thalassaemia major presents with fatigue and failure to thrive. Blood tests show microcytic, hypochromic anaemia with a haemoglobin of 60 g/L and nucleated red blood cells on the film. What is the underlying pathophysiological cause of these clinical findings?
a) Antibody-mediated destruction of red blood cells
b) Reduced production of alpha-globin chains causing haemoglobin precipitation
c) Iron deficiency due to poor dietary intake
d) Reduced production of beta-globin chains leading to ineffective erythropoiesis and haemolysis
Answer:
d) Reduced production of beta-globin chains leading to ineffective erythropoiesis and haemolysis
Rationale: Beta-thalassaemia major is characterised by a severe deficiency/absence of beta-globin chain synthesis. This causes an excess of alpha chains, which precipitate in erythroid precursors, leading to ineffective erythropoiesis, haemolysis, and severe anaemia. The presence of nucleated RBCs reflects intense bone marrow expansion.
Q2:
Which of the following statements accurately describes the inheritance pattern and carrier status for sickle cell disease (SCD)?
a) It is autosomal dominant; carriers are mildly symptomatic
b) It is X-linked recessive; only males are affected
c) It is autosomal recessive; carriers (HbAS) are typically asymptomatic but can pass the mutation
d) It is mitochondrial; inherited from the mother only
Answer:
c) It is autosomal recessive; carriers (HbAS) are typically asymptomatic but can pass the mutation
Rationale: SCD, like thalassaemia, follows an autosomal recessive pattern. An individual must inherit two abnormal alleles (HbSS) to have the disease. Heterozygous carriers (HbAS) have sickle cell trait and are generally asymptomatic under normal conditions, though they can pass the sickle allele to offspring.
Q3:
A patient with sickle cell disease (HbSS) is admitted with a sudden, severe headache and left-sided weakness. Urgent CT scan is negative for haemorrhage. What is the most likely acute complication and the critical long-term preventive intervention for this?
a) Acute Chest Syndrome; prophylactic hydroxycarbamide
b) Vaso-occlusive Crisis; regular blood transfusions
c) Acute Splenic Sequestration; scheduled splenectomy
d) Ischaemic Stroke; regular transcranial Doppler (TCD) screening and chronic transfusion program
Answer:
d) Ischaemic Stroke; regular transcranial Doppler (TCD) screening and chronic transfusion program
Rationale: Stroke is a devastating complication of SCD, primarily ischaemic due to vasculopathy. TCD ultrasonography is used annually from age 2 to identify children at high risk, who are then placed on a chronic transfusion program to reduce stroke risk by lowering the percentage of HbS.
Q4:
Hydroxycarbamide (hydroxyurea) is a key disease-modifying therapy in sickle cell disease. What is its primary mechanism of action?
a) Chelates excess iron to prevent overload
b) Inhibits sickling by blocking haemoglobin S polymerisation
c) Stimulates the production of fetal haemoglobin (HbF)
d) Reduces red cell adhesion to the endothelium
Answer:
c) Stimulates the production of fetal haemoglobin (HbF)
Rationale: Hydroxycarbamide increases the production of HbF. HbF does not incorporate into the HbS polymer and dilutes the concentration of HbS within the red cell, thereby reducing polymerisation, sickling, and the frequency of vaso-occlusive crises.
Q5:
A pregnant woman from a high-risk ethnic background is found to be a carrier for beta-thalassaemia. Her partner is screened and is also a carrier. What is the risk for their child having beta-thalassaemia major?
a) 0%
b) 25%
c) 50%
d) 100%
Answer:
b) 25%
*Rationale: As both parents are carriers (heterozygous), each pregnancy has a 25% chance of the child inheriting two abnormal alleles (homozygous = thalassaemia major), a 50% chance of being a carrier, and a 25% chance of being unaffected.*
Q6:
A patient with sickle cell disease requires a splenectomy due to recurrent acute splenic sequestration crises. What is the most important prophylactic measure post-splenectomy?
a) Lifelong therapeutic anticoagulation with warfarin
b) Regular iron chelation therapy
c) Lifelong penicillin V prophylaxis and appropriate vaccinations
d) Monthly exchange blood transfusions
Answer:
c) Lifelong penicillin V prophylaxis and appropriate vaccinations
Rationale: The spleen is vital for clearing encapsulated bacteria. Post-splenectomy, patients are at lifelong risk of overwhelming post-splenectomy infection (OPSI). Prophylactic antibiotics (e.g., penicillin V) and vaccinations against Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis are essential.
Q7:
Which of the following haemoglobinopathies results from the deletion of three out of the four alpha-globin genes?
a) Alpha-plus thalassaemia carrier (silent carrier)
b) Haemoglobin Bart's Hydrops Fetalis
c) Haemoglobin H Disease
d) Beta-thalassaemia intermedia
Answer:
c) Haemoglobin H Disease
*Rationale: Alpha-thalassaemia severity depends on the number of functional alpha-globin genes. Three non-functional genes (one remaining) results in HbH disease, characterised by moderate-to-severe anaemia due to excess beta chains forming unstable HbH (β4).*
Q8:
The new gene therapy Exagamglogene Autotemcel (Casgevy) for sickle cell disease utilises CRISPR-Cas9 technology. What is its primary genetic target?
a) Correcting the A>T point mutation in the HBB gene
b) Inserting a normal copy of the beta-globin gene via a lentiviral vector
c) Editing the BCL11A gene enhancer to reactivate fetal haemoglobin (HbF) production
d) Knocking out the P-selectin gene to reduce vaso-occlusion
Answer:
c) Editing the BCL11A gene enhancer to reactivate fetal haemoglobin (HbF) production
*Rationale: Casgevy uses CRISPR to edit the erythroid-specific enhancer of the BCL11A gene, a repressor of HbF. Disrupting this enhancer reduces BCL11A expression, allowing reactivation of HbF synthesis, which ameliorates the disease.*
Q9:
A patient with HbSC disease (sickle cell C disease) is most likely to present with which of the following clinical patterns?
a) Severe, frequent vaso-occlusive crises but mild anaemia
b) Systemic symptoms milder than HbSS, but severe ocular pathology (proliferative retinopathy)
c) Severe, transfusion-dependent anaemia from infancy
d) Asymptomatic carrier state
Answer:
b) Systemic symptoms milder than HbSS, but severe ocular pathology (proliferative retinopathy)
Rationale: HbSC disease often has a milder systemic course than HbSS, with less severe anaemia and fewer crises. However, patients are at particularly high risk for severe ocular complications like proliferative retinopathy and retinal detachment due to increased blood viscosity.
Q10:
What is the evolutionary explanation for the high prevalence of the sickle cell trait (HbAS) in malaria-endemic regions?
a) HbAS confers complete immunity to all forms of malaria
b) Plasmodium falciparum infection is less likely to occur in individuals with HbAS
c) Red blood cells containing HbS sickle when infected, leading to their removal by the spleen and hindering parasite replication
d) Individuals with HbAS have higher iron levels, which inhibits parasite growth
Answer:
c) Red blood cells containing HbS sickle when infected, leading to their removal by the spleen and hindering parasite replication
Rationale: This is the classic example of balanced polymorphism. In low-oxygen environments (like those created by the malaria parasite), HbAS red cells sickle. These infected, sickled cells are preferentially cleared by the spleen, reducing parasite burden and conferring a survival advantage against severe P. falciparum malaria.
Section 2: Extended Matching Questions (EMQ) Set
Theme: Complications and Management of Sickle Cell Disease
Options:
A) Acute Chest Syndrome
B) Vaso-occlusive (Painful) Crisis
C) Acute Splenic Sequestration
D) Stroke (Cerebrovascular Accident)
E) Priapism
F) Avascular Necrosis (of femoral/humeral head)
G) Leg Ulcers
H) Cholelithiasis (Gallstones)
I) Osteomyelitis
J) Proliferative Retinopathy
For each clinical presentation below, select the SINGLE MOST LIKELY complication from the list above.
1)
A 5-year-old child with HbSS presents with sudden onset of pallor, tachycardia, lethargy, and a markedly enlarged, tender spleen. Haemoglobin has dropped from 80 to 40 g/L.
Answer:
C) Acute Splenic Sequestration
Rationale: This is a classic presentation of acute splenic sequestration, a life-threatening crisis where blood pools in the spleen, causing rapid anaemia, hypovolaemia, and splenomegaly.
2)
A 25-year-old man with HbSS presents with fever, cough, chest pain, and new infiltrates on chest X-ray. Oxygen saturation is 88% on room air.
Answer:
A) Acute Chest Syndrome
Rationale: ACS is a leading cause of death in SCD, characterised by fever, respiratory symptoms, hypoxaemia, and new pulmonary infiltrates. It can be triggered by infection, fat embolism, or infarction.
3)
An 18-year-old with SCD has had a persistent, painful erection lasting 4 hours.
Answer:
E) Priapism
*Rationale: Priapism is a urological emergency in SCD, caused by sickling and vaso-occlusion in the corpora cavernosa. Stuttering priapism (brief episodes) is common, but an episode lasting >4 hours requires urgent intervention to prevent ischaemic damage.*
4)
A 30-year-old woman with HbSC disease reports gradual worsening of her vision. Ophthalmoscopy reveals neovascularisation and retinal haemorrhages.
Answer:
J) Proliferative Retinopathy
Rationale: Proliferative retinopathy is a particularly severe complication of HbSC disease (more so than HbSS). Retinal ischaemia leads to neovascularisation, which can cause vitreous haemorrhage and retinal detachment.
5)
A 12-year-old with SCD presents with sudden severe pain in the right hip and a limp. MRI shows subchondral collapse of the femoral head.
Answer:
F) Avascular Necrosis (of femoral/humeral head)
Rationale: AVN is a common chronic complication due to vaso-occlusion of the blood supply to weight-bearing joints, most commonly the femoral head. It causes pain and can lead to early-onset osteoarthritis.
6)
An 8-year-old child with a history of frequent transfusions for SCD presents with right tibial pain, fever, and localised swelling. X-ray shows a periosteal reaction.
Answer:
I) Osteomyelitis
Rationale: Patients with SCD are at increased risk of osteomyelitis, often due to Salmonella or Staphylococcus aureus. Differentiating it from a vaso-occlusive bone infarct can be challenging, but fever and specific radiographic signs can point to infection.
7)
A 40-year-old man with HbSS has chronic, non-healing wounds around his medial malleoli.
Answer:
G) Leg Ulcers
Rationale: Chronic leg ulcers are a debilitating complication, typically occurring around the ankles. They result from poor circulation, hypoxia, and trauma, and are difficult to heal.
8)
A 22-year-old with SCD presents to A&E with severe, sharp lower back and bilateral thigh pain. There is no fever or neurological deficit. This is her typical crisis pain.
Answer:
B) Vaso-occlusive (Painful) Crisis
Rationale: This is the hallmark acute complication of SCD. It is caused by microvascular occlusion from sickled RBCs, leading to tissue ischaemia and severe pain, most commonly in the back, long bones, and chest.
9)
A 10-year-old with SCD on a chronic transfusion program develops right upper quadrant pain, especially after fatty meals. Ultrasound shows multiple stones in the gallbladder.
Answer:
H) Cholelithiasis (Gallstones)
Rationale: Chronic haemolysis leads to bilirubin excess and the formation of pigment (bilirubinate) gallstones. This is extremely common in SCD, with many children developing stones by adolescence
10)
A 6-year-old with SCD has a sudden onset of right-sided facial droop and arm weakness.
Answer:
D) Stroke (Cerebrovascular Accident)
Rationale: Children with SCD are at very high risk of ischemic stroke due to cerebral vasculopathy. This is a neurological emergency requiring immediate transfusion and long-term preventative strategies.
Section 3: Integrated Long Answer Clinical Scenario
Scenario: Amira, a 22-year-old university student known to have sickle cell disease (HbSS), presents to the Emergency Department. She reports 48 hours of severe, unremitting lower back and bilateral thigh pain, not relieved by her home analgesia (paracetamol and codeine). She also reports a mild cough and feeling feverish over the past day. She mentions she has been stressed with exams and has not been drinking well.
Past Medical History: Multiple vaso-occlusive crises, one episode of acute chest syndrome aged 15. On hydroxycarbamide 1.5g daily, folic acid 5mg daily, and penicillin V prophylaxis. Up-to-date with vaccinations.
Observations: Temp 38.1°C, HR 118 bpm, BP 105/70, RR 24 breaths/min, SpO₂ 93% on room air.
Initial Bloods: Hb 70 g/L (baseline 80-90), WBC 15.2 x 10⁹/L, Neutrophils 12.5 x 10⁹/L, Platelets 450 x 10⁹/L, Reticulocytes 12%. CRP 85 mg/L.
Chest X-ray: New small opacity at the right lung base.
Q: As the reviewing clinical pharmacist, develop a comprehensive management plan for Amira. Your plan must address:
The immediate management of her acute presentation.
A review and plan for her long-term disease-modifying therapy.
Key monitoring parameters and follow-up.
Important patient counselling points for discharge.
In-depth Answer:
1. IMMEDIATE ACUTE MANAGEMENT:
Diagnosis: This is likely a severe Vaso-Occlusive Crisis (VOC) with developing Acute Chest Syndrome (ACS). Triggers include dehydration (poor intake) and possible infection (fever, cough, elevated WBC/CRP, new CXR finding).
Prioritised Interventions:
A. Oxygen: Start supplemental oxygen to maintain SpO₂ >95% (targets for SCD are higher to prevent sickling).
B. Analgesia (TIME-CRITICAL): Initiate prompt, aggressive opioid analgesia via a protocol-driven pathway (e.g., IV morphine or equivalent via PCA pump). Use regular scheduled dosing, not PRN. Add a non-opioid adjunct (e.g., regular paracetamol, NSAID like ibuprofen if renal function is normal).
C. Hydration: Commence IV fluids (e.g., 0.9% saline + 5% dextrose) to correct dehydration and reduce blood viscosity. Avoid over-hydration (risk of pulmonary oedema).
D. Infection Management: Broad-spectrum IV antibiotics (e.g., co-amoxiclav or a cephalosporin + macrolide) to cover community-acquired pneumonia, a common trigger for ACS.
E. Respiratory Support: Involve physiotherapy for incentive spirometry to prevent atelectasis and worsening ACS.
F. Transfusion Consideration: Monitor closely. Simple top-up transfusion may be needed if Hb drops significantly (<50 g/L or >20g below baseline). Exchange transfusion is indicated if ACS worsens (SpO₂ dropping, increasing respiratory distress, enlarging infiltrates) or if severe multi-organ involvement occurs.
G. Hydroxycarbamide: CONTINUE her usual dose unless she becomes pancytopenic. Do not stop it during crisis.
2. REVIEW OF LONG-TERM DISEASE-MODIFYING THERAPY:
Hydroxycarbamide (Hydroxyurea) Adherence & Dose:
Verify adherence history. Stress and illness are common reasons for lapses.
Check recent FBC and MCV. The goal of therapy is to maximise HbF. A good response is indicated by:
Increased Hb (by 1-2 g/dL) and MCV (macrocytosis).
Reduced WBC and platelet counts.
Reduced frequency of crises.
Dose Assessment: 1.5g daily = ~21 mg/kg for a 70kg patient. This is within the standard 15-20 mg/kg/day range but may be suboptimal. Consider checking an HbF level. If <20% and she is still having severe crises, discuss with haematology about dose escalation (max usually 35 mg/kg/day), provided she is not myelosuppressed.
Consideration of Advanced Therapies:
Given her history of recurrent crises and ACS, she may be a candidate for additional disease-modifying therapy.
Discussion Points with Haematology:
Crizanlizumab (P-selectin inhibitor): Though withdrawn from EU/UK markets, the concept of targeting adhesion is valid.
Voxelotor (HbS polymerisation inhibitor): Also withdrawn, but newer agents may follow.
Curative Options: Bone Marrow Transplant (HSCT) or Gene Therapy (e.g., Casgevy). She should be informed about these options, their risks (chemo/radiotherapy conditioning, graft-vs-host disease for HSCT), and eligibility criteria for potential future referral.
3. KEY MONITORING & FOLLOW-UP:
Inpatient Monitoring:
Vitals: Hourly respiratory rate, SpO₂, pain scores.
Clinical: Respiratory exam, pain control, fluid balance.
Laboratory: Daily FBC, CRP. Repeat CXR if respiratory status changes.
Outpatient Follow-up:
Sickle Specialist Clinic: Review within 2-4 weeks post-discharge.
Monitoring Tests: FBC, LFTs, Renal Function, Reticulocytes, HbF %, Serum Ferritin (if transfused). Annual TCD (if not on chronic transfusion), Echocardiogram (for pulmonary hypertension), Ophthalmology review.
Comprehensive Annual Review: Assess for chronic complications (renal, pulmonary, avascular necrosis, leg ulcers, psychosocial health).
4. PATIENT COUNSELLING FOR DISCHARGE:
Crisis Prevention:
Hydration: Emphasise drinking 3-4 litres daily, especially during stress/exams.
Avoid Triggers: Extreme temperatures (cold can precipitate crisis), strenuous over-exertion, smoking.
Infection Vigilance: Continue penicillin V. Seek immediate medical advice for any fever >38.5°C.
Medication Adherence:
Reinforce the importance of taking hydroxycarbamide daily, even when well. Provide a pill organiser if needed.
Discuss potential side effects (myelosuppression, skin/nail changes) and the need for regular blood tests.
Self-Management & Safety Netting:
Ensure she has a personalised crisis plan: including contact details, usual effective analgesia regimen, and clear "red flag" symptoms (fever, chest pain, shortness of breath, severe headache, priapism >1 hour).
Advise her to present early to hospital for pain not controlled at home.
Discuss university support services (disability support, counselling) to manage academic stress.
Psychosocial Support: Acknowledge the chronic disease burden. Refer to or provide details for specialist sickle cell counsellors and patient advocacy groups (e.g., Sickle Cell Society).